达沙替尼治疗伊马替尼耐药的慢性粒细胞白血病的研究进展(3)

http://www.100md.com 2010年8月1日 《医学信息·中旬刊》 2010年第8期

     [14]Guilhot F,Apperley J,et al.Efficacy of dasatinib in patients with accelerated phase chronic myelogenous leukemia with resistance or intolerance to imatinib:2 year follow-up data from START-A(CA180-005).Blood (ASH Annual Meeting Abstracts Nov),2007).2008,110:470.

    [15]Cortes J,Rousselot P,et al.Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis.Blood,2007,109(8):3207-3213.

    [16]Gambacorti C,Cortes J,et al.Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib:2-year follow-up data from the START Program.Blood.(ASH Annual Meeting Abstracts),2007,110:472.

    [17]Shah NP,Kantarjian HM,et al.Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia.J Clin Oncol,2008,26(19):3204-3212.

    [18]Quintas-Cardama A,Kantarjian H,et al.Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.J Clin Oncol,2007,25(25):3908-3914.

    [19]Punnialingam S,de Lavallade H,et al.Pleural effusions associated with use of dasatinib in chronic myeloid leukemia may have an auto-immune pathogenesis.Blood.(ASH Annual Meeting Abstracts),2007,110:2945.

    [20]Mustjoki S,Laurinolli T,et al.Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy.Blood.(ASH Annual Meeting Abstracts),2007,110:2938.

上一页 第 1 2 3 页

    百拇医药网 http://www.100md.com/html/paper/1006-1959A/2010/08/322-2.htm